abstract |
The present invention relates to a fusion protein comprising a cytokine antagonist and a targeting moiety, preferably an antibody or antibody-like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine that binds to the receptor but does not induce receptor signaling. The present invention also relates to a fusion protein according to the invention for use in the treatment of cancer and immune- or inflammation-related disorders. |